BENEVICH ERIC
SEC CIK 1643653 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | Chief Commercial Off | 70.7K | — | $40.02M | 41 | 2021-08-16 | 2026-09-11 |
Most active insiders at NBIX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | GORMAN KEVIN CHARLES | Dir | — | $37.82M |
| 2 | Cooke Julie | CHRO | — | $5.77M |
| 3 | Gano Kyle | CEO, Dir | — | $4.87M |
| 4 | Lippoldt Darin | CLO | — | $4.20M |
| 5 | SHERWIN STEPHEN A | Dir | — | $4.13M |
| 6 | Delaet Ingrid | Chief Regulatory Off | — | $3.75M |
| 7 | Onyia Jude | CSO | — | $3.47M |
| 8 | RASTETTER WILLIAM H | Dir | — | $2.73M |
| 9 | POPS RICHARD F | Dir | — | $2.36M |
| 10 | LYONS GARY A | Dir | — | $2.29M |
| 13 | BENEVICH ERIC | Chief Commercial Off | — | $1.24M |
Transactions 41
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 17:02 | 2026-09-11 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | A - Grant | $0.00 | +6,275 | 70.7K | +10% | $0 | |
| 2026-09-15 17:02 | 2026-09-11 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | F - Tax | $156.22 | -3,386 | 67.3K | -5% | -$529.0K | |
| DT | 2026-09-10 20:29 | 2026-09-09 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $43.24 | +3,194 | 66.6K | +5% | +$138.1K |
| DT | 2026-09-10 20:29 | 2026-09-09 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $154.61 | -2,154 | 64.4K | -3% | -$333.0K |
| DM | 2026-02-17 | 2026-02-12+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | +6,049 | 56.7K | +12% | $0 |
| DM | 2026-02-17 | 2026-02-12+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | F - Tax | $124.03 | -12.2K | 63.2K | -16% | -$1.52M |
| D | 2026-02-17 | 2026-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | A - Grant | $0.00 | +16.6K | 72.2K | +30% | $0 |
| D | 2026-02-03 | 2026-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | +2,294 | 54.0K | +4% | $0 |
| D | 2026-02-03 | 2026-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | F - Tax | $136.06 | -1,292 | 52.8K | -2% | -$175.8K |
| DA | 2026-01-16 | 2025-11-28 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $35.99 | +12.8K | 57.7K | +29% | +$461.8K |
| D | 2025-12-02 | 2025-11-28 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $35.99 | +5,970 | 50.9K | +13% | +$214.9K |
| D | 2025-12-02 | 2025-11-28 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $151.74 | -5,970 | 44.9K | -12% | -$905.9K |
| DM | 2025-02-14 | 2025-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | +4,044 | 45.7K | +10% | $0 |
| DM | 2025-02-14 | 2025-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $116.73 | -2,154 | 43.8K | -5% | -$251.4K |
| D | 2025-02-12 | 2025-02-08 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | +1,860 | 43.8K | +4% | $0 |
| D | 2025-02-12 | 2025-02-10 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $118.31 | -980 | 42.8K | -2% | -$115.9K |
| D | 2025-02-04 | 2025-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | +2,294 | 43.1K | +6% | $0 |
| D | 2025-02-04 | 2025-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $152.94 | -1,207 | 41.9K | -3% | -$184.6K |
| DM | 2024-04-17 | 2024-04-15 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $81.21 | +19.8K | 48.0K | +70% | +$1.61M |
| DM | 2024-04-17 | 2024-04-15 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $133.36 | -19.8K | 40.8K | -33% | -$2.64M |
| DM | 2024-03-15 | 2024-03-14 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $80.90 | +75.0K | 110.3K | +212% | +$6.07M |
| DM | 2024-03-15 | 2024-03-14 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $139.38 | -75.0K | 40.8K | -65% | -$10.45M |
| DM | 2024-02-29 | 2024-02-28 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $134.69 | -75.0K | 40.6K | -65% | -$10.10M |
| DM | 2024-02-29 | 2024-02-28 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $53.67 | +75.0K | 93.8K | +400% | +$4.03M |
| D | 2024-02-15 | 2024-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $133.01 | -1,098 | 40.6K | -3% | -$146.0K |
| M | 2024-02-08 | 2024-02-06+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $138.68 | -2,260 | 39.6K | -5% | -$313.4K |
| 2024-02-02 | 2024-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $140.78 | -1,207 | 37.6K | -3% | -$169.9K | |
| 2023-08-23 | 2023-08-21 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $107.40 | -1,600 | 36.4K | -4% | -$171.8K | |
| M | 2023-02-08 | 2023-02-06+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $102.70 | -19.6K | 33.5K | -37% | -$2.02M |
| 2023-02-02 | 2023-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $109.95 | -1,207 | 16.7K | -7% | -$132.7K | |
| D | 2023-01-10 | 2023-01-06 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $43.24 | +400 | 16.0K | +3% | +$17.3K |
| D | 2023-01-10 | 2023-01-06 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $125.00 | -400 | 15.6K | -2% | -$50.0K |
| DM | 2022-12-01 | 2022-11-30 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $41.47 | +50.0K | 35.7K | New | +$2.07M |
| DM | 2022-12-01 | 2022-11-30 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $125.90 | -50.0K | 15.6K | -76% | -$6.29M |
| DM | 2022-11-10 | 2022-11-08+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $41.78 | +24.7K | 15.7K | New | +$1.03M |
| DM | 2022-11-10 | 2022-11-08+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $125.33 | -24.7K | 15.6K | -61% | -$3.09M |
| DM | 2022-11-04 | 2022-11-02+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $125.02 | -9,368 | 15.6K | -37% | -$1.17M |
| DM | 2022-11-04 | 2022-11-02+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $41.78 | +9,368 | 16.0K | +140% | +$391.4K |
| 2022-10-19 | 2022-10-17 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $110.82 | -4,960 | 15.6K | -24% | -$549.7K | |
| M | 2022-02-09 | 2022-02-07+ | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $80.57 | -5,099 | 19.5K | -21% | -$410.8K |
| 2021-08-18 | 2021-08-16 | NBIX | NEUROCRINE BIOSCIENCES INC | BENEVICH ERIC | Chief Commercial Off | S - Sale | $89.62 | -5,628 | 15.6K | -27% | -$504.4K |
Purchase Sale Sale after option exercise All abbreviations